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Previous studieshave reported alterations of glial cells and particu-
larly astrocytes in mood disorders. Therefore, serum concentra-
tion of the astrocytic marker S100B was ascertained with an
immunoluminometric assay in 20 patients with mood disorder
and 12 healthy age-matched controls. Serum S100B was elevated
in major depression (median after admission 410ng/l, at discharge
o 100ng/l) andmania (130,160ng/l), when comparedwith controls
(o 100ng/l; po 0.01). Antidepressive treatment reduced S100B in
conjunction with severity of depressive symptoms (po 0.01). The
severity of depression (HamiltonDepression Rating Scale) was po-
sitively correlatedwith S100B (rs¼ 0.51, po 0.005).Elevated serum
S100B during depressive and manic episodes of mood disorders
may indicate alterations of astrocytes, which are reversed by
antidepressive treatment. NeuroReport 13:1675^1678 c 2002
LippincottWilliams &Wilkins.
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INTRODUCTION
S100 proteins are acidic Ca2þ-binding proteins which may
influence several cellular responses along the Ca2þ-signal
transduction pathway [1]. The monomer S100B is found in
the CNS, especially in the cytoplasm of astrocytes. S100B
has a mol.wt of B10 kDa and can form homodimers or
heterodimers with S100A1. It regulates cell shape, energy
metabolism, contraction, cell-to-cell communication, intra-
cellular signal transduction and cell growth [2], and can be
actively released by astrocytes [3]. Interestingly, the effects
of extracellular S100B depend on its concentration [1].
Nanomolar concentrations act as growth and/or differentia-
tion factor for neurons and astrocytes, whereas micromolar
concentrations may induce apoptosis, for instance in
pheochromocytoma cells. Serum S100B has been used as a
marker for structural damage to the brain, particularly to
astrocytes, for instance after cardiopulmonary bypass [4]
and severe head injury [5]. Increased serum S100B levels
may be due to leakage of the astrocytic membrane [4].
Neuroimaging studies have shown that the volume of
several brain regions is decreased in mood disorders [6]. For
instance, the mean gray matter volume of the subgenual
prefrontal cortex is abnormally reduced in familial major
depression or bipolar disorder [7], which may be due in part
to reduction of glial cells [8]. Another study [9] demon-
strated morphological alterations of astrocytes in the
dorsolateral prefrontal cortex of patients with unipolar
major depression.
In summary, serum levels of S100B may be a suitable
marker for damage to the brain, and particularly for
alterations of astrocytes [4]. Moreover, in mood disorders
cerebral morphological abnormalities are known that
include reduction of glial cells [8] and alteration of
astrocytes [9], in areas of the prefrontal cortex. Therefore,
we examined S100B serum levels and hypothesized that
S100B is elevated in patients with major depression and
mania in comparison with healthy controls, and that S100B
is reduced by treatment.
MATERIALS AND METHODS
Patients consisted of nine subjects with severe major
depression (age 21–69; four female) and 11 subjects with a
severe manic episode of bipolar disorder (age 31–57 years;
four female), who were hospitalized in the Department of
Psychiatry. Depression and mania were diagnosed indepen-
dently by two psychiatrists according to the criteria of the
diagnostic and statistical manual of mental disorders (DSM
IV) [10] and the international classification of diseases (ICD-
10) [11]. The semi-structured interview according to the
AMDP system (Arbeitsgemeinschaft fu¨r Methodik und
Dokumentation in der Psychiatrie) and ICD-10 checklists
were used for diagnosis [12]. Systemic diseases (neoplasms,
autoimmune diseases, infectious diseases, cardiovascular
and neurological diseases), comorbid diagnosis and drug or
alcohol abuse were ruled out by taking a detailed history,
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reviewing charts, physical examination and measuring body
temperature, C-reactive protein, and erythrocyte sedimenta-
tion rate. Healthy controls were recruited from the medical
personnel (age 34–60 years; eight female). Disorders as
mentioned above and psychiatric disorders were excluded
by taking a detailed history. The controls were not taking
any drugs.
Patients with mood disorder were treated according to the
guidelines of the American Psychiatric Association [13,14].
Treatment was not interrupted during hospitalization. There
were no differences between depressive patients, manic
patients and controls concerning mean (7 s.d.) age
(44.47 18.1, 44.27 8.4, 43.87 9.4 years, one-way ANOVA
df¼ 2, F¼ 0.01, p4 0.05), total lifetime duration of illness
(4.17 7.1, 9.67 7.3 years; 2-tailed Student’s t-test t¼ 1.71,
p4 0.05), and age at onset of first episode (40.37 19.3,
34.57 8.6 years; t¼0.84, p4 0.05). Only the number of
episodes differed between depressive and manic patients
(2.87 2.2, 6.97 4.1; t¼ 2.89, po 0.05). The severity of
depressive symptoms was assessed with the 21-item
Hamilton Depression Rating Scale (HAMD) [15], and the
severity of manic symptoms with the Bech-Rafaelsen Mania
Scale (BRMAS) [16]. Treatment significantly reduced the
severity of depression (HAMD score at admission
23.37 3.1, at discharge 6.17 6.6, n¼ 7; 2-tailed paired
Student’s t-test, t¼ 5.14, po 0.005), and the severity of
mania (BRMAS score at admission 19.67 2.8, at discharge
3.67 3.6, n¼ 5; t¼ 6.64, po 0.005). The Brief Psychiatric
Rating Scale (BPRS) was used additionally in patients with
psychotic symptoms [17]. Clinical ratings were performed
on the same or one day before/after determining S100B. The
investigation was carried out in accordance with the latest
version of the Declaration of Helsinki. Written informed
consent was obtained from the subjects. The research
protocol was approved by the local ethics committee.
Blood samples were obtained by venipuncture from
patients after admission to hospital, which was followed
by approximately weekly venipuncture until discharge.
Follow up was impossible in some (especially manic)
patients because of lack of cooperation or discharge after
o 1 week. Venipuncture was generally performed at
08.00 h. Within 2 h the serum samples were centrifuged
(21C, 3500 r.p.m., 10 min), and stored at 701C until
analysis. Serum S100B was determined with a monoclonal
two-site immunoluminometric assay (LIA-mat Sangtec-100,
AB Sangtec Medical, Bromma, Sweden).
Some values were below the detection limit of 100 ng/l.
Therefore, we report median values and used non-para-
metric tests. Treatment effects were analyzed with Friedman
two-way ANOVA followed by the Wilcoxon matched-pairs
test. Patients and controls were compared using the Mann-
Whitney test. Correlation analysis was performed according
to Spearman.
RESULTS
For every patient, S100B concentration after admission to
the hospital, the highest value during hospitalization and
value at discharge were included in the analysis (Fig. 1). The
respective highest value of S100B during hospitalization
was included, because both S100B and the severity of
depression increased in some patients during the initial time
period of hospitalization. Serum S100B was below the
detection limit of 100 ng/l in all 12 healthy controls. S100B
values were significantly higher in depressive patients at
admission (median 410 ng/l, n¼ 9, z¼3.6, po 0.001), with
respect to highest values (median 410 ng/l, n¼ 9, z¼4.3,
po 0.001), and at discharge (median o 100 ng/l, n¼ 7,
z¼2.4, po 0.01; 1-tailed Mann-Whitney test) in compar-
ison with the controls. Serum S100B was also significantly
elevated in patients with mania, when compared with S100B
in the controls (median at admission 130, regarding highest
values 170, at discharge 160 ng/l; n ¼ 11, 11, 5; z¼3.5,
3.8, 3.4; po 0.001, respectively).
To assess the impact of antidepressive and antimanic
treatment on serum S100B, values at discharge were
compared with values after admission and the respective
highest values during hospitalization for both patient
groups. Antidepressive treatment reduced S100B signifi-
cantly in depressive patients (Friedman two-way ANOVA;
w2¼ 10.1, df¼ 2, po 0.01), in conjunction with decreasing
Fig.1. S100B serumconcentration in patientswithmajor depression and
mania. Box-whisker-plots for values at admission (Admission; n¼ 9;11),
highest values during hospitalization (Maximum; n¼ 9;11), and values at
discharge (Discharge; n¼ 7; 5). #po 0.05, ##po 0.01 in comparison
with values at discharge (Wilcoxon test). **po 0.01, ***po 0.001 in
comparisonwith healthy controls (n¼12; Mann-Whitney test).Values be-
low the detection limit of 100 ng/l are reported as 99ng/l. S100B was
o 100ng/l in all controls.
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the clinical severity of depression (see above). The post hoc
Wilcoxon matched-pairs tests revealed significantly lower
serum S100B at discharge in comparison with values after
admission and the respective highest values during hospi-
talization (1-tailed; n¼ 7; z¼1.9, 2.4; p¼ 0.05, po 0.01,
respectively). There was no significant influence of anti-
manic treatment on serum S100B in patients with mania
(Friedman two-way ANOVA; w2¼ 3.9, df¼ 2, p4 0.05). The
severity of depression as rated with the HAMD correlated
significantly with serum S100B in depressive patients if all
measured time points were analyzed together (rs¼ 0.51,
n¼ 31, po 0.005; Spearman, 2-tailed). However, the severity
of mania, as rated with the BRMAS, did not correlate with
S100B (rs¼0.08, n¼ 18, p4 0.05). Further, the third sub-
score (thought disturbance) of the BPRS was positively
correlated with S100B (rs¼ 0.84, n¼ 6, po 0.05) in depres-
sion with psychotic features.
In the following analysis, the highest S100B concentration
of each case during hospitalization was related to age,
number of episodes and total lifetime duration of the
disorder. In mania, S100B was negatively correlated with
total lifetime duration of the disorder (rs¼0.81, n¼ 11,
po 0.005). If data of all patients with mood disorders were
analyzed, S100B was negatively correlated with total
lifetime duration of the disorder and age (rs¼0.45,
rs¼0.47, n¼ 20, po 0.05, respectively).
DISCUSSION
This study shows that S100B serum concentrations are
increased during episodes of mood disorders when com-
pared with healthy controls and are reduced during
antidepressive treatment. Thus, our results are in accor-
dance with literature data, which reported increased
concentrations of S100B in the cerebrospinal fluid during
mild or moderate depressive episodes [18], and demon-
strated increased serum S100B in patients with melancholic
major depression in comparison with healthy controls [19].
If one considers S100B as an astrocyte specific protein [1],
data may indicate alterations of astrocytes during episodes
of mood disorders which are reversed by antidepressive
treatment. Interestingly, serum concentrations of neuron-
specific enolase are not elevated in major depression and
mania, demonstrating an intact neuronal structure ([20] and
unpublished data). Results agree nicely with histopatholo-
gical post mortem studies reporting alterations of glial cells
[8,21,22] or astrocytes [9] in specific prefrontal brain regions
of patients with mood disorders. Summarizing the studies,
the assumption [21] can be supported that there is disease-
specific glial pathology in mood disorders.
Two different causes may increase serum values of S100B
in patients with mood disorders as found in our study. On
the one hand, S100B might be increased due to injury of
astrocytes and a disrupted integrity of the blood–brain
barrier, as S100B, with a mol. wt of 10 kDa, may not pass
through the intact blood–brain barrier [4,5]. This assump-
tion is supported by studies showing reduced volumes [6,7],
and diminished densities of glial cells [8,21,22] in several
brain regions in mood disorders. Further, the blood-brain
barrier is disrupted in depression as measured with the
cerebrospinal fluid/serum ratio for albumin [23]. Because
astrocytes induce and maintain the proper function of the
blood–brain barrier [24,25], injury of astrocytes may lead to
its disruption. However, increases of S100B as found in our
study are relevant to astrocytes and more than just
indicative of a subtle increase in permeability of the
blood–brain barrier, because serum neuron-specific enolase
is unchanged in major depression and mania ([20] and
unpublished data).
On the other hand, serum S100B might be increased
during episodes of mood disorders due to active secretion of
S100B by astrocytes [1–3]. Extracellular S100B may stimulate
neurite outgrowth, differentiation, or induce apoptosis, for
instance in pheochromocytoma cells, depending on its
concentration [1,2]. Moreover, S100B possesses autocrine
functions since it stimulates astrocytic proliferation [3].
However, the action of secreted S100B is unclear as it
depends on concentration [1,2]. In contrast, antidepressive
drugs may reduce the release of S100B by astrocytes, since
they predominantly target the adrenergic and serotonergic
neurotransmitter system [9], and the serotonergic system
may influence serum S100B [2].
CONCLUSION
Our results show that serum concentrations of S100B are
increased during depressive and manic episodes of mood
disorders. These data may suggest structural or functional
alterations of astrocytes in these disorders. In contrast,
antidepressive medication seems to reverse these alterations
in conjunction with the reduction of clinical depression.
Therefore, serum S100B can be of additional diagnostic
value in mood disorders.
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